Abstracts tagged "Cardiovascular disease"

Abstract Number: 1479 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Diseases and Mortality Are Independently Influenced By Carotid Plaque Presence in Rheumatoid Arthritis: The 5-Year Prospective Study
Jung Su Eun¹, Eun Song Lee², Jong Wan Kang¹, Na Ri Kim¹, Ji Hun Kim¹, Jin Young Kang¹, Eon Jeong Nam³ and Young Mo Kang¹, ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, ²Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD) and premature mortality, compared to the general population. Inflammatory burden and conventional…
Abstract Number: 1782 • 2016 ACR/ARHP Annual Meeting
Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Laura Geraldino-Pardilla¹, Thania Perez², Sabahat Bokhari³, Joan Bathon⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : Cardiovascular disease (CVD) remains a leading cause of death in SLE. Lupus patients have a 2-3 fold increased risk to develop heart failure…
Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 233 • 2016 ACR/ARHP Annual Meeting
New Cardiovascular Risk Factors Screening in Patients with Gout
Juan Carlos Ordoñez¹, Mariano Andres¹, Francisca Sivera², Loreto Carmona³, Paloma Vela^4,5, Eliseo Pascual^4,5 and Jose Antonio Bernal⁴, ¹RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ELDA, Elda, Spain, ³Instituto de Salud Musculo Esqueletica, Madrid, Spain, ⁴RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO ALICANTE, Alicante, Spain, ⁵Medicina, Universidad Miguel Hernandez, Elche, Spain
Background/Purpose: Gout is a disease triggered by the crystallization of uric acid in the joints secondary to persistent hyperuricemia, that leads to chronic inflammation. Patients…
Abstract Number: 905 • 2016 ACR/ARHP Annual Meeting
Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis
Richard Conway¹, Anne Madigan², Laura Helbert³, Niamh Redmond⁴, Eimear Dunne⁵, Eamonn S. Molloy⁶, Dermot Kenny⁵ and Geraldine M. McCarthy⁷, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁴UCD Clinical Research Centre, Dublin, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland, ⁷Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with Giant Cell Arteritis (GCA) have an increased risk of devastating cranial ischaemic complications including vision loss and stroke. The BSR guidelines recommend…
Abstract Number: 1480 • 2016 ACR/ARHP Annual Meeting
Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Willem F. Lems^1,3 and Mike T. Nurmohamed^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. This cardiovascular risk is mainly determined by the lipid profile, which may change…
Abstract Number: 1786 • 2016 ACR/ARHP Annual Meeting
Long-Term Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus in a Large Case Control Cohort Study
Konstantinos Tselios¹, Dafna D Gladman², Jiandong Su³, Olga Ace⁴ and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Certain traditional and disease-related factors have been identified to accelerate atherosclerosis in systemic lupus erythematosus (SLE). Due to the lack of long-term prospective studies,…
Abstract Number: 2549 • 2016 ACR/ARHP Annual Meeting
Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients
Maria Vanesa Hernandez-Hernandez¹, Esmeralda Delgado-Frias², Beatriz Tejera³, Cristina Luna Gomez⁴, Jose Ramon Muñiz^5,6, De Vera-González AM⁷, Sagrario Bustabad⁸, Ivan Ferraz-Amaro⁸ and Federico Díaz-González⁹, ¹Rheumatology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ²Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ³Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁴Rosario S/N, H. Ntra. Sra. La Candelaria, Santa Cruz de Teneri, Spain, ⁵Radiology, Hospital Universitario de Canarias, San Cristobal de la Laguna, Spain, ⁶Radiology, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁷Central Laboratory Division, Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁹Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) has been acknowledged to increase cardiovascular mortality probably due, in part, to a lipid profile different from that observed in the…
Abstract Number: 259 • 2016 ACR/ARHP Annual Meeting
Rituximab in Refractory Cardiac Sarcoidosis – Single Center Experience
Megan Krause¹, Leslie T. Cooper Jr.², Panithaya Chareonthaitawee³ and Shreyasee Amin¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiology, Mayo Clinic, Jacksonville, FL, ³Cardiology, Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac sarcoidosis is a life threatening condition for which there is limited data to guide optimal steroid-sparing agents. B-cells have been reported to…
Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting
Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study
Amar Oza¹, Na Lu² and Hyon K. Choi³, ¹Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, ²Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…
Abstract Number: 1481 • 2016 ACR/ARHP Annual Meeting
Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases
Silvia Rollefstad, Pia Norheim, Eirik Ikdahl and Anne Grete Semb, Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The excess risk of cardiovascular disease (CVD) in patients with inflammatory joint diseases (IJD) is attributable to several risk factors, including a high prevalence…
Abstract Number: 1792 • 2016 ACR/ARHP Annual Meeting
Cardiac Surgery in Systemic Lupus Erythematosus Patients: Clinical Characteristics and Outcomes
Lauro Quintanilla-González¹, Javier Tejeda-Maldonado², Jaime Galindo-Uribe³ and Andrea Hinojosa-Azaola⁴, ¹Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Cardiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: To study the clinical characteristics and outcomes of Systemic Lupus Erythematosus (SLE) patients that underwent cardiac surgery. Methods: Retrospective analysis of 30 SLE patients…
Abstract Number: 2579 • 2016 ACR/ARHP Annual Meeting
Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis
Atul A. Deodhar¹, Bojena Bitman², Yue Yang² and David Collier³, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Amgen Inc., South San Francisco, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease. This analysis evaluated changes in metabolic and lipid CV risk factors…
Abstract Number: 260 • 2016 ACR/ARHP Annual Meeting
Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson² and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Risk of Cardiovascular Disease Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Several epidemiologic studies have demonstrated an increased incidence of atherosclerotic cardiovascular…
Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].